Improvements throughout the pipeline bring greater biologic yields, as well as higher quality. by Raymond E Peck, CEO of VxP Biologics Improvements throughout the pipeline bring greater biologic yields, as well as lower costs. Bioprocessing is the production of natural or genetically manipulated cells (or other organic parts). In the field of biologic pharmaceuticals, bioprocessing [...]
Emerging technologies offer exciting opportunities for the development of novel therapies. by Susan Thompson, Technical Director at VxP Biologics Although commercial sales are certainly a desirable target for pharmaceutical development, they’re far from the only reason to invest in new products. In a number of fields, pharma developers are partnering with contract manufacturing organizations (CMOs) [...]
As the biologics market expands, developers need support from expert contractors. by Raymond E Peck, CEO of VxP Biologics A growing number of pharmaceutical development companies are partnering with contract manufacturing organizations (CMOs) to meet the global demand for biologics. This investment comes with good reason: as of 2016, the global biopharmaceutical market was valued [...]
Although lyophilization (freeze-drying) is a costly, time-consuming process, it offers a number of major advantages over simpler dosage forms. by Raymond E Peck, CEO of VxP Biologics Tablets and capsules can create problems for patients with nausea or difficulty swallowing; syringes can carry risk of infection; and even certain drugs administered from vials can take [...]
